Skip to main content

Advertisement

SpringerLink
Log in

The association between MMP2 −1306 C > T (rs243865) polymorphism and risk of prostate cancer

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Prostate cancer is the second most common cancer in men. Matrix metalloproteinase-2 (MMP2) is the most important member of the matrix metalloproteinase family. MMP2 digests the basement membrane and causes changes in the extracellular matrix which in turn facilitate cancer invasion. It, therefore, has a major role in tumor angiogenesis. Previous studies have identified a single-nucleotide polymorphism C/T at position −1306 of MMP2 gene promoter which is a key regulatory factor in cancer progression.

Aim

The present study aimed to determine the association between MMP2 polymorphism and the risk of prostate cancer in Iranian men.

Methods

This case–control study was performed on 50 paraffin-embedded prostate cancer tissue samples and 54 blood samples from healthy men. Genotyping of the samples was performed using high-resolution melting analysis (HRM). Finally, 20 % of the genotypes were confirmed by sequencing.

Results

No significant associations were found between CT and TT genotypes and the risk of prostate cancer. However, there were no significant relationships between the genotypes and the studied factors, e.g., age, pathological stage, and Gleason Score.

Conclusion

MMP2 −1306 C > T (rs243865) polymorphism was not significantly related with prostate cancer susceptibility in Iranian men.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  2. Carter BS, Carter HB, Isaacs JT (1990) Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 16:187–197

    Article  CAS  PubMed  Google Scholar 

  3. Bishop JL, Davies A, Ketola K et al (2015) Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endoc Relat Cancer 22:165–182

    Article  Google Scholar 

  4. Bookstein R, MacGrogan D, Hilsenbeck SG et al (1993) p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369–3373

    CAS  PubMed  Google Scholar 

  5. Björndahl M, Cao R, Nissen LJ et al (2005) Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 102:15593–15598

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hojilla CV, Mohammed FF, Khokha R (2003) Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 89:1817–1821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Forget MA, Desrosiers RR, Béliveau R (1999) Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 77:465–480

    Article  CAS  PubMed  Google Scholar 

  8. Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270

    Article  CAS  PubMed  Google Scholar 

  9. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174

    Article  CAS  PubMed  Google Scholar 

  10. Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA et al (2008) Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 65:68–72

    Article  CAS  PubMed  Google Scholar 

  11. Ozalp S, Tanir HM, Yalcin OT et al (2003) Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol 24:417–420

    CAS  PubMed  Google Scholar 

  12. Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276:7549–7558

    Article  CAS  PubMed  Google Scholar 

  13. Ogawa K, Chen F, Kuang C et al (2004) Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem J 381:413–422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yu C, Zhou Y, Miao X et al (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622–7628

    Article  CAS  PubMed  Google Scholar 

  15. Chan PK, Chan DP, To KF et al (2001) Evaluation of extraction methods from paraffin wax embedded tissues for PCR amplification of human and viral DNA. J Clin Pathol 54:401–403

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Pharoah PD, Dunning AM, Ponder BA et al (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4:850–860

    Article  CAS  PubMed  Google Scholar 

  17. Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85

    Article  CAS  PubMed  Google Scholar 

  18. Yoon SO, Park SJ, Yun CH et al (2003) Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36:128–137

    CAS  PubMed  Google Scholar 

  19. Curran S, Murray GI (1999) Matrix metalloproteinases in tumor invasion and metastasis. J Pathol 189:300–308

    Article  CAS  PubMed  Google Scholar 

  20. Stamenkovic I (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10:415–433

    Article  CAS  PubMed  Google Scholar 

  21. Sternlicht MD, Werb Z (1999) In: Kreis T, Vale R (eds) Guidebook to the extracellular matrix and adhesion proteins. Oxford University Press, Oxford, UK, pp 503–562

  22. Ye S (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19:623–629

    Article  CAS  PubMed  Google Scholar 

  23. Bian J, Sun Y (1997) Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17:6330–6338

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Qin H, Sun Y, Benveniste EN (1999) The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 274:29130–29137

    Article  CAS  PubMed  Google Scholar 

  25. Jacobs EJ, Hsing AW, Bain EB et al (2008) Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev 17:972–977

    Article  CAS  PubMed  Google Scholar 

  26. Haque S, Akhter N, Lohani M et al (2015) Matrix Metalloproteinase-2−1306 C > T Gene Polymorphism is Associated with Reduced Risk of Cancer: a Meta-analysis. Asian Pac J Cancer Prev 16:889–896

    Article  PubMed  Google Scholar 

  27. Liu D, Guo H, Li Y et al (2012) Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One 7:e31251

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Peng B, Cao L, Ma X et al (2010) Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis 25:371–379

    Article  CAS  PubMed  Google Scholar 

  29. Yaykaşli KO, Kayikçi MA, Yamak N et al (2014) Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. Turk J Med Sci 44:839–843

    Article  PubMed  Google Scholar 

  30. Elander N, Söderkvist P, Fransén K (2006) Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res 26:791–795

    CAS  PubMed  Google Scholar 

  31. McColgan P, Sharma P (2009) Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer 125:1473–1478

    Article  CAS  PubMed  Google Scholar 

  32. Kader AK, Shao L, Dinney CP et al (2006) Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 66:11644–11648

    Article  CAS  PubMed  Google Scholar 

  33. Xu E, Lai M, Lv B et al (2004) A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res. Commun 324:999–1003

    Article  CAS  PubMed  Google Scholar 

  34. Yu C, Pan K, Xing D et al (2002) Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 62:6430–6433

    CAS  PubMed  Google Scholar 

  35. Miao X, Yu C, Tan W et al (2003) A functional polymorphism in the matrix metalloproteinase-2 gene promoter (−1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinomal. Cancer Res 63:3987–3990

    CAS  PubMed  Google Scholar 

  36. Zhou Y, Yu C, Miao X et al (2004) Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25:399–404

    Article  CAS  PubMed  Google Scholar 

  37. Grieu F, Li WQ, Iacopetta B (2004) Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 88:197–204

    Article  CAS  PubMed  Google Scholar 

  38. Dos Reis ST, Villanova FE, De Andrade PM (2008) Polymorphisms of the matrix metalloproteinases associated with prostate cancer. Mol Med Rep 1:517–520

    PubMed  Google Scholar 

  39. Dos Reis ST, Villanova FE, Andrade PM (2010) Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer. Urol Oncol 28:624–627

    Article  PubMed  Google Scholar 

  40. Srivastava P, Lone TA, Kapoor R et al (2012) Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in north India. Arch Med Res 43:117–124

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The provision of specimens by pathology department of Modarres Hospital (Tehran, Iran) and Kaj laboratory is gratefully acknowledged.

Author information

Authors and Affiliations

  1. Department of Biology, Faculty of Biological Sciences, Parand Branch, Islamic Azad University, Parand, Iran

    L. Shajarehpoor Salavati & F. Tafvizi

  2. Department of Pharmaceutical Nanotechnology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran

    H. K. Manjili

Authors
  1. L. Shajarehpoor Salavati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Tafvizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. K. Manjili
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Tafvizi.

Ethics declarations

Conflicts of interest

The authors declare no conflicts of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All ethical considerations are considered in this study. The present case–control study was conducted after obtaining written informed consent from qualified patients interested in participating in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shajarehpoor Salavati, L., Tafvizi, F. & Manjili, H.K. The association between MMP2 −1306 C > T (rs243865) polymorphism and risk of prostate cancer. Ir J Med Sci 186, 103–111 (2017). https://doi.org/10.1007/s11845-016-1492-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-016-1492-9

Keywords

Search

Navigation